Low-Dose Thymoglobulin versus Basiliximab Induction Therapy in Low-Risk Living Related Kidney Transplant Recipients: Three-Year Follow-Up Study
The optimal dose of rabbit anti-thymocyte globulin (r-ATG) in renal transplantation is still under debate. We previously reported that a low-dose r-ATG induction of 3 mg/kg can be used safely and effectively in low-risk kidney transplants with good results in the first year after transplantation com...
Gespeichert in:
Veröffentlicht in: | Archives of medical research 2024-09, Vol.55 (6), p.103047, Article 103047 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 6 |
container_start_page | 103047 |
container_title | Archives of medical research |
container_volume | 55 |
creator | Martinez-Mier, Gustavo Moreno-Ley, Pedro I. Budar-Fernández, Luis F. Méndez-López, Marco T. Allende-Castellanos, Carlos A. Jiménez-López, Luis A. Barrera-Amoros, Daniel A. Reyes-Ruiz, José Manuel |
description | The optimal dose of rabbit anti-thymocyte globulin (r-ATG) in renal transplantation is still under debate. We previously reported that a low-dose r-ATG induction of 3 mg/kg can be used safely and effectively in low-risk kidney transplants with good results in the first year after transplantation compared to basiliximab induction.
The purpose of this study is to evaluate the long-term impact of this trial of low-dose r-ATG versus basiliximab on post-transplant outcomes (patient and graft survival, biopsy-proven acute rejection incidence [BPAR], infectious complications, and side effects).
Observational study (three-year follow-up) of a 12-month single-center, open-label RCT in de novo kidney allograft recipients assigned to receive either thymoglobulin or basiliximab before transplantation.
Patients in the basiliximab group (BG) underwent more kidney transplant biopsies than patients in the low-dose r-ATG group (TG) (50 vs. 31.8%, p = 0.07). Although the 12-month cumulative incidence of BPAR was lower in BG, by the end of the three-year follow-up period this incidence was higher (22%) than in the low-dose TG (15%) (p = ns). Steroids were withdrawn more frequently in the TG group and sirolimus was most frequently indicated. Graft function and graft survival were higher in the low-dose TG than in the BG at three-year follow-up but not statistically significant. Patient survival was similar between groups (>90%).
These three-year follow-up data confirm the efficacy and favorable safety aspects of the low-dose r-ATG (3 mg/kg) in low-risk kidney transplantation. |
doi_str_mv | 10.1016/j.arcmed.2024.103047 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3086380037</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0188440924000997</els_id><sourcerecordid>3086380037</sourcerecordid><originalsourceid>FETCH-LOGICAL-c241t-147b0975e284b0ec85418e269f7f50ea93432c9dd801b69d319080fc000c03c23</originalsourceid><addsrcrecordid>eNp9kcFu1DAURS0EokPhDxDykk2G59iT2CyQoFCoGAmpTBesLMd-KR4ycWonA_kKfhmP0m5ZWfI79z77XkJeMlgzYNWb_dpEe0C3LqEU-YqDqB-RFZM1LzZC1o_JCpiUhRCgzsizlPYAIEVVPyVnXEGthIQV-bsNv4uPISHd_ZwP4bYLzdT5nh4xpinRDyb5zv_xB9PQq95NdvShzyhGM8w0cyf5tU-_6NYffX9Lr7EzIzr61bseZ7qLpk9DZ_oxT6wfPPZjepsNImLxA02kl6HrssfNQL-Pk5ufkyet6RK-uD_Pyc3lp93Fl2L77fPVxfttYUvBxoKJugFVb7CUogG0ciOYxLJSbd1uAI3igpdWOSeBNZVynCmQ0NocgQVuS35OXi--Qwx3E6ZRH3yy2OWnYpiS5iArLgF4nVGxoDaGlCK2eog5kDhrBvpUhd7rpQp9qkIvVWTZq_sNU3OaPYgess_AuwXA_M-jx6iTzflYdD6iHbUL_v8b_gGUWpzj</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3086380037</pqid></control><display><type>article</type><title>Low-Dose Thymoglobulin versus Basiliximab Induction Therapy in Low-Risk Living Related Kidney Transplant Recipients: Three-Year Follow-Up Study</title><source>Elsevier ScienceDirect Journals</source><creator>Martinez-Mier, Gustavo ; Moreno-Ley, Pedro I. ; Budar-Fernández, Luis F. ; Méndez-López, Marco T. ; Allende-Castellanos, Carlos A. ; Jiménez-López, Luis A. ; Barrera-Amoros, Daniel A. ; Reyes-Ruiz, José Manuel</creator><creatorcontrib>Martinez-Mier, Gustavo ; Moreno-Ley, Pedro I. ; Budar-Fernández, Luis F. ; Méndez-López, Marco T. ; Allende-Castellanos, Carlos A. ; Jiménez-López, Luis A. ; Barrera-Amoros, Daniel A. ; Reyes-Ruiz, José Manuel</creatorcontrib><description>The optimal dose of rabbit anti-thymocyte globulin (r-ATG) in renal transplantation is still under debate. We previously reported that a low-dose r-ATG induction of 3 mg/kg can be used safely and effectively in low-risk kidney transplants with good results in the first year after transplantation compared to basiliximab induction.
The purpose of this study is to evaluate the long-term impact of this trial of low-dose r-ATG versus basiliximab on post-transplant outcomes (patient and graft survival, biopsy-proven acute rejection incidence [BPAR], infectious complications, and side effects).
Observational study (three-year follow-up) of a 12-month single-center, open-label RCT in de novo kidney allograft recipients assigned to receive either thymoglobulin or basiliximab before transplantation.
Patients in the basiliximab group (BG) underwent more kidney transplant biopsies than patients in the low-dose r-ATG group (TG) (50 vs. 31.8%, p = 0.07). Although the 12-month cumulative incidence of BPAR was lower in BG, by the end of the three-year follow-up period this incidence was higher (22%) than in the low-dose TG (15%) (p = ns). Steroids were withdrawn more frequently in the TG group and sirolimus was most frequently indicated. Graft function and graft survival were higher in the low-dose TG than in the BG at three-year follow-up but not statistically significant. Patient survival was similar between groups (>90%).
These three-year follow-up data confirm the efficacy and favorable safety aspects of the low-dose r-ATG (3 mg/kg) in low-risk kidney transplantation.</description><identifier>ISSN: 0188-4409</identifier><identifier>ISSN: 1873-5487</identifier><identifier>EISSN: 1873-5487</identifier><identifier>DOI: 10.1016/j.arcmed.2024.103047</identifier><identifier>PMID: 39079480</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Basiliximab ; Kidney transplantation ; Post-trial follow-up study ; Thymoglobulin</subject><ispartof>Archives of medical research, 2024-09, Vol.55 (6), p.103047, Article 103047</ispartof><rights>2024 Instituto Mexicano del Seguro Social (IMSS)</rights><rights>Copyright © 2024 Instituto Mexicano del Seguro Social (IMSS). Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c241t-147b0975e284b0ec85418e269f7f50ea93432c9dd801b69d319080fc000c03c23</cites><orcidid>0000-0002-2883-9188 ; 0000-0001-7021-5101</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0188440924000997$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39079480$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Martinez-Mier, Gustavo</creatorcontrib><creatorcontrib>Moreno-Ley, Pedro I.</creatorcontrib><creatorcontrib>Budar-Fernández, Luis F.</creatorcontrib><creatorcontrib>Méndez-López, Marco T.</creatorcontrib><creatorcontrib>Allende-Castellanos, Carlos A.</creatorcontrib><creatorcontrib>Jiménez-López, Luis A.</creatorcontrib><creatorcontrib>Barrera-Amoros, Daniel A.</creatorcontrib><creatorcontrib>Reyes-Ruiz, José Manuel</creatorcontrib><title>Low-Dose Thymoglobulin versus Basiliximab Induction Therapy in Low-Risk Living Related Kidney Transplant Recipients: Three-Year Follow-Up Study</title><title>Archives of medical research</title><addtitle>Arch Med Res</addtitle><description>The optimal dose of rabbit anti-thymocyte globulin (r-ATG) in renal transplantation is still under debate. We previously reported that a low-dose r-ATG induction of 3 mg/kg can be used safely and effectively in low-risk kidney transplants with good results in the first year after transplantation compared to basiliximab induction.
The purpose of this study is to evaluate the long-term impact of this trial of low-dose r-ATG versus basiliximab on post-transplant outcomes (patient and graft survival, biopsy-proven acute rejection incidence [BPAR], infectious complications, and side effects).
Observational study (three-year follow-up) of a 12-month single-center, open-label RCT in de novo kidney allograft recipients assigned to receive either thymoglobulin or basiliximab before transplantation.
Patients in the basiliximab group (BG) underwent more kidney transplant biopsies than patients in the low-dose r-ATG group (TG) (50 vs. 31.8%, p = 0.07). Although the 12-month cumulative incidence of BPAR was lower in BG, by the end of the three-year follow-up period this incidence was higher (22%) than in the low-dose TG (15%) (p = ns). Steroids were withdrawn more frequently in the TG group and sirolimus was most frequently indicated. Graft function and graft survival were higher in the low-dose TG than in the BG at three-year follow-up but not statistically significant. Patient survival was similar between groups (>90%).
These three-year follow-up data confirm the efficacy and favorable safety aspects of the low-dose r-ATG (3 mg/kg) in low-risk kidney transplantation.</description><subject>Basiliximab</subject><subject>Kidney transplantation</subject><subject>Post-trial follow-up study</subject><subject>Thymoglobulin</subject><issn>0188-4409</issn><issn>1873-5487</issn><issn>1873-5487</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kcFu1DAURS0EokPhDxDykk2G59iT2CyQoFCoGAmpTBesLMd-KR4ycWonA_kKfhmP0m5ZWfI79z77XkJeMlgzYNWb_dpEe0C3LqEU-YqDqB-RFZM1LzZC1o_JCpiUhRCgzsizlPYAIEVVPyVnXEGthIQV-bsNv4uPISHd_ZwP4bYLzdT5nh4xpinRDyb5zv_xB9PQq95NdvShzyhGM8w0cyf5tU-_6NYffX9Lr7EzIzr61bseZ7qLpk9DZ_oxT6wfPPZjepsNImLxA02kl6HrssfNQL-Pk5ufkyet6RK-uD_Pyc3lp93Fl2L77fPVxfttYUvBxoKJugFVb7CUogG0ciOYxLJSbd1uAI3igpdWOSeBNZVynCmQ0NocgQVuS35OXi--Qwx3E6ZRH3yy2OWnYpiS5iArLgF4nVGxoDaGlCK2eog5kDhrBvpUhd7rpQp9qkIvVWTZq_sNU3OaPYgess_AuwXA_M-jx6iTzflYdD6iHbUL_v8b_gGUWpzj</recordid><startdate>20240901</startdate><enddate>20240901</enddate><creator>Martinez-Mier, Gustavo</creator><creator>Moreno-Ley, Pedro I.</creator><creator>Budar-Fernández, Luis F.</creator><creator>Méndez-López, Marco T.</creator><creator>Allende-Castellanos, Carlos A.</creator><creator>Jiménez-López, Luis A.</creator><creator>Barrera-Amoros, Daniel A.</creator><creator>Reyes-Ruiz, José Manuel</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2883-9188</orcidid><orcidid>https://orcid.org/0000-0001-7021-5101</orcidid></search><sort><creationdate>20240901</creationdate><title>Low-Dose Thymoglobulin versus Basiliximab Induction Therapy in Low-Risk Living Related Kidney Transplant Recipients: Three-Year Follow-Up Study</title><author>Martinez-Mier, Gustavo ; Moreno-Ley, Pedro I. ; Budar-Fernández, Luis F. ; Méndez-López, Marco T. ; Allende-Castellanos, Carlos A. ; Jiménez-López, Luis A. ; Barrera-Amoros, Daniel A. ; Reyes-Ruiz, José Manuel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c241t-147b0975e284b0ec85418e269f7f50ea93432c9dd801b69d319080fc000c03c23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Basiliximab</topic><topic>Kidney transplantation</topic><topic>Post-trial follow-up study</topic><topic>Thymoglobulin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Martinez-Mier, Gustavo</creatorcontrib><creatorcontrib>Moreno-Ley, Pedro I.</creatorcontrib><creatorcontrib>Budar-Fernández, Luis F.</creatorcontrib><creatorcontrib>Méndez-López, Marco T.</creatorcontrib><creatorcontrib>Allende-Castellanos, Carlos A.</creatorcontrib><creatorcontrib>Jiménez-López, Luis A.</creatorcontrib><creatorcontrib>Barrera-Amoros, Daniel A.</creatorcontrib><creatorcontrib>Reyes-Ruiz, José Manuel</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Archives of medical research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Martinez-Mier, Gustavo</au><au>Moreno-Ley, Pedro I.</au><au>Budar-Fernández, Luis F.</au><au>Méndez-López, Marco T.</au><au>Allende-Castellanos, Carlos A.</au><au>Jiménez-López, Luis A.</au><au>Barrera-Amoros, Daniel A.</au><au>Reyes-Ruiz, José Manuel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Low-Dose Thymoglobulin versus Basiliximab Induction Therapy in Low-Risk Living Related Kidney Transplant Recipients: Three-Year Follow-Up Study</atitle><jtitle>Archives of medical research</jtitle><addtitle>Arch Med Res</addtitle><date>2024-09-01</date><risdate>2024</risdate><volume>55</volume><issue>6</issue><spage>103047</spage><pages>103047-</pages><artnum>103047</artnum><issn>0188-4409</issn><issn>1873-5487</issn><eissn>1873-5487</eissn><abstract>The optimal dose of rabbit anti-thymocyte globulin (r-ATG) in renal transplantation is still under debate. We previously reported that a low-dose r-ATG induction of 3 mg/kg can be used safely and effectively in low-risk kidney transplants with good results in the first year after transplantation compared to basiliximab induction.
The purpose of this study is to evaluate the long-term impact of this trial of low-dose r-ATG versus basiliximab on post-transplant outcomes (patient and graft survival, biopsy-proven acute rejection incidence [BPAR], infectious complications, and side effects).
Observational study (three-year follow-up) of a 12-month single-center, open-label RCT in de novo kidney allograft recipients assigned to receive either thymoglobulin or basiliximab before transplantation.
Patients in the basiliximab group (BG) underwent more kidney transplant biopsies than patients in the low-dose r-ATG group (TG) (50 vs. 31.8%, p = 0.07). Although the 12-month cumulative incidence of BPAR was lower in BG, by the end of the three-year follow-up period this incidence was higher (22%) than in the low-dose TG (15%) (p = ns). Steroids were withdrawn more frequently in the TG group and sirolimus was most frequently indicated. Graft function and graft survival were higher in the low-dose TG than in the BG at three-year follow-up but not statistically significant. Patient survival was similar between groups (>90%).
These three-year follow-up data confirm the efficacy and favorable safety aspects of the low-dose r-ATG (3 mg/kg) in low-risk kidney transplantation.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>39079480</pmid><doi>10.1016/j.arcmed.2024.103047</doi><orcidid>https://orcid.org/0000-0002-2883-9188</orcidid><orcidid>https://orcid.org/0000-0001-7021-5101</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0188-4409 |
ispartof | Archives of medical research, 2024-09, Vol.55 (6), p.103047, Article 103047 |
issn | 0188-4409 1873-5487 1873-5487 |
language | eng |
recordid | cdi_proquest_miscellaneous_3086380037 |
source | Elsevier ScienceDirect Journals |
subjects | Basiliximab Kidney transplantation Post-trial follow-up study Thymoglobulin |
title | Low-Dose Thymoglobulin versus Basiliximab Induction Therapy in Low-Risk Living Related Kidney Transplant Recipients: Three-Year Follow-Up Study |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T19%3A43%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Low-Dose%20Thymoglobulin%20versus%20Basiliximab%20Induction%20Therapy%20in%20Low-Risk%20Living%20Related%20Kidney%20Transplant%20Recipients:%20Three-Year%20Follow-Up%20Study&rft.jtitle=Archives%20of%20medical%20research&rft.au=Martinez-Mier,%20Gustavo&rft.date=2024-09-01&rft.volume=55&rft.issue=6&rft.spage=103047&rft.pages=103047-&rft.artnum=103047&rft.issn=0188-4409&rft.eissn=1873-5487&rft_id=info:doi/10.1016/j.arcmed.2024.103047&rft_dat=%3Cproquest_cross%3E3086380037%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3086380037&rft_id=info:pmid/39079480&rft_els_id=S0188440924000997&rfr_iscdi=true |